### Summary Report: Baxter's Third Quarter Earnings Conference

#### Financial Overview
- **Third-quarter 2021 global sales:** $3.2 billion, an increase of 9% on a reported basis, 7% on a constant currency basis, and 6% operationally.
- **Adjusted earnings per share (EPS):** $1.02, an increase of 23% compared to last year, surpassing guidance.
- **Gross margin:** Improved to 44%, up 140 basis points year-over-year.
- **Operating cash flow:** $1.5 billion year-to-date with free cash flow exceeding $1.0 billion.
  
#### Key Performance Drivers
1. **BioPharma Solutions:** Recorded substantial growth of 45% at constant currency rates, primarily driven by revenue from COVID-19 vaccine manufacturing.
2. **Medication Delivery:** Grew 11% at constant currency, benefiting from increased hospital admissions and demand for infusion products.
3. **Pharmaceuticals:** Increased by 7% on a constant currency basis, with operational growth at 1%. Growth was driven by international pharmacy compounding and sales of Caelyx/Doxil following the acquisition of rights outside the U.S.
4. **Renal Care:** Increased modestly by 1% on a constant currency basis.
5. **Clinical Nutrition and Advanced Surgery:** Both segments showed improvement, benefiting from new product launches and recovery in surgical volumes internationally.

#### Strategic Initiatives
- **Acquisition of Hillrom:** A major strategic move set to broaden the product range and enhance global reach. The acquisition is on track to close by early 2022 following the expiration of the Hart-Scott-Rodino waiting period.
- **Innovation and Market Expansion:** Focused on accelerating innovation to meet evolving customer needs, especially in the face of the COVID-19 pandemic.
- **Environmental, Social, and Governance (ESG):** Strengthened commitment through a new UNICEF partnership and recognition in Forbes' list of globally praised employers.

#### Challenges and Outlook
- **Market Conditions:** Continued variability in pandemic recovery rates and elective procedure volumes, influenced by the Delta variant and ongoing hospital staffing issues.
- **Inflationary Pressures:** Addressing rising costs related to raw materials, commodities, and supply chain disruptions.
- **Full Year 2021 Projections:** Global sales are expected to grow between 7% and 8% on a reported basis. Adjusted EPS forecasted to be between $3.58 and $3.62.

#### Investment Stance: Overweight
Given the strong Q3 performance exceeding expectations, robust strategic initiatives such as the Hillrom acquisition, and effective management of inflationary pressures, Baxter presents a compelling investment opportunity. The company's diversified portfolio and strategic expansion efforts potentially position it for sustained growth, making it an attractive option for overweight positioning in investment portfolios.

### Closing Remarks
The integration of Hillrom represents a transformative opportunity for Baxter, promising substantial long-term value creation. The continued focus on innovation, operational excellence, and strategic market expansion underpins our positive outlook on Baxter's financial health and market position.